Immco, headquartered in Buffalo, New York, and employing 90 people, is a diagnostic company specializing in the development, manufacture and sale of autoimmune test kits on a worldwide basis. Immco’s product line is complemented by specialized reference laboratory services in diagnostic immunology, pathology and immunogenetics, marketed to US-based reference laboratories and hospitals.

Convergence had been engaged by Immco and its financial sponsor Summit Partners, to pursue a sale of the Company. Convergence worked actively with Immco CEO Bill Maggio to craft a strategic marketing plan for the company that maximized value with an optimal acquisition partner. Convergence managed a highly efficient, but fully marketed auction sale process that enabled a closed transaction to be finalized and closed less than 18 weeks after the launch of the process. Ireland-based Trinity Biotech acquired Immco to augment its diagnostics product suite with the addition of Immco’s leading suite of Autoimmune diagnostics products.